Annals of Coloproctology

Display

Sort by :

Original Articles

Colorectal cancer

Efficacy of preoperative chemoradiotherapy in patients with cT2N0 distal rectal cancer: Min Young Park, Chang Sik Yu, Tae Won Kim, Jong Hoon Kim, Jin-hong Park, Jong Lyul Lee, Yong Sik Yoon, In Ja Park, Seok-Byung Lim, Jin Cheon Kim; Ann Coloproctol. 2023;39(3):250-259. Published online April 4, 2022; DOI: https://doi.org/10.3393/ac.2022.00066.0009

5,768 View
160 Download
7 Web of Science
5 Citations

Graphical Abstract Abstract PDF Supplementary Material

Purpose
This study was designed to determine the feasibility of preoperative chemoradiotherapy (PCRT) in patients with clinical T2N0 distal rectal cancer.
Methods
Patients who underwent surgery for clinical T2N0 distal rectal cancer between January 2008 and December 2016 were included. Patients were divided into PCRT and non-PCRT groups. Non-PCRT patients underwent radical resection or local excision (LE) according to the surgeon’s decision, and PCRT patients underwent surgery according to the response to PCRT. Patients received 50.0 to 50.4 gray of preoperative radiotherapy with concurrent chemotherapy.
Results
Of 127 patients enrolled, 46 underwent PCRT and 81 did not. The mean distance of lesions from the anal verge was lower in the PCRT group (P=0.004). The most frequent operation was transanal excision and ultralow anterior resection in the PCRT and non-PCRT groups, respectively. Of the 46 patients who underwent PCRT, 21 (45.7%) achieved pathologic complete response, including 15 of the 24 (62.5%) who underwent LE. Rectal sparing rate was significantly higher in the PCRT group (11.1% vs. 52.2%, P<0.001). There were no significant differences in 3- and 5-year overall survival and recurrence-free survival regardless of PCRT or surgical procedures.
Conclusion
PCRT in clinical T2N0 distal rectal cancer patients increased the rectal sparing rate via LE and showed acceptable oncologic outcomes. PCRT may be a feasible therapeutic option to avoid abdominoperineal resection in clinical T2N0 distal rectal cancer.

Citations

Citations to this article as recorded by

Lymph node metastasis following chemoradiotherapy in advanced rectal cancer: ypT2-focused analyses of total mesorectal excision specimens
A. N. Singhi, T.-G. Lee, H.-M. Ahn, H.-R. Shin, M. J. Choi, M. H. Jo, H.-K. Oh, D.-W. Kim, S.-B. Kang
Techniques in Coloproctology.2025;[Epub] CrossRef
Performance reporting design in artificial intelligence studies using image-based TNM staging and prognostic parameters in rectal cancer: a systematic review
Minsung Kim, Taeyong Park, Bo Young Oh, Min Jeong Kim, Bum-Joo Cho, Il Tae Son
Annals of Coloproctology.2024; 40(1): 13. CrossRef
Comparative analysis of organ preservation attempt and radical surgery in clinical T2N0 mid to low rectal cancer
Hyeung-min Park, Jaram Lee, Soo Young Lee, Chang Hyun Kim, Hyeong Rok Kim
International Journal of Colorectal Disease.2024;[Epub] CrossRef
Organ preservation for early rectal cancer using preoperative chemoradiotherapy
Gyung Mo Son
Annals of Coloproctology.2023; 39(3): 191. CrossRef
Unveiling the profound advantages of total neoadjuvant therapy in rectal cancer: a trailblazing exploration
Kyung Uk Jung, Hyung Ook Kim, Hungdai Kim, Donghyoun Lee, Chinock Cheong
Annals of Surgical Treatment and Research.2023; 105(6): 341. CrossRef

Malignant disease,Colorectal cancer,Benign diesease & IBD,Biomarker & risk factor

Molecular characterization of dysplasia-initiated colorectal cancer with assessing matched tumor and dysplasia samples: Sungwon Jung, Jong Lyul Lee, Tae Won Kim, Jongmin Lee, Yong Sik Yoon, Kil Yeon Lee, Ki-hwan Song, Chang Sik Yu, Yong Beom Cho; Ann Coloproctol. 2022;38(1):72-81. Published online November 17, 2021; DOI: https://doi.org/10.3393/ac.2021.00290.0041

5,523 View
135 Download
2 Web of Science
2 Citations

Abstract PDF

Purpose
Ulcerative colitis (UC) is known to have an association with the increased risk of colorectal cancer (CRC), and UC-associated CRC does not follow the typical progress pattern of adenoma-carcinoma. The aim of this study is to investigate molecular characteristics of UC-associated CRC and further our understanding of the association between UC and CRC.
Methods
From 5 patients with UC-associated CRC, matched normal, dysplasia, and tumor specimens were obtained from formalin-fixed paraffin-embedded (FFPE) samples for analysis. Genomic DNA was extracted and whole exome sequencing was conducted to identify somatic variations in dysplasia and tumor samples. Statistical analysis was performed to identify somatic variations with significantly higher frequencies in dysplasia-initiated tumors, and their relevant functions were investigated.
Results
Total of 104 tumor mutation genes were identified with higher mutation frequencies in dysplasia-initiated tumors. Four of the 5 dysplasia-initiated tumors (80.0%) have TP53 mutations with frequent stop-gain mutations that were originated from matched dysplasia. APC and KRAS are known to be frequently mutated in general CRC, while none of the 5 patients have APC or KRAS mutation in their dysplasia and tumor samples. Glycoproteins including mucins were also frequently mutated in dysplasia-initiated tumors.
Conclusion
UC-associated CRC tumors have distinct mutational characteristics compared to typical adenoma-carcinoma tumors and may have different cancer-driving molecular mechanisms that are initiated from earlier dysplasia status.

Citations

Citations to this article as recorded by

Impact of Postoperative Naples Prognostic Score to Predict Survival in Patients with Stage II–III Colorectal Cancer
Su Hyeong Park, Hye Seung Woo, In Kyung Hong, Eun Jung Park
Cancers.2023; 15(20): 5098. CrossRef
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus R0 resection for resectable colorectal cancer with peritoneal metastases and low peritoneal cancer index scores: A collaborative observational study from Korea and Japan
Daichi Kitaguchi, Eun Jung Park, Seung Hyuk Baik, Shoma Sasaki, Yuichiro Tsukada, Masaaki Ito
International Journal of Surgery.2023;[Epub] CrossRef

Prognostic Factors in Terms of the Number of Metastatic Nodules in Patients With Colorectal Cancer Liver Metastases: Ki Ung Jang, Chan Wook Kim, Ki-Hun Kim, Seok-Byung Lim, Chang Sik Yu, Tae Won Kim, Pyo Nyun Kim, Jong Hoon Kim, Jin Cheon Kim; Ann Coloproctol. 2016;32(3):92-100. Published online June 30, 2016; DOI: https://doi.org/10.3393/ac.2016.32.3.92

6,501 View
38 Download
17 Web of Science
14 Citations

Abstract PDF

Purpose

The hepatic resection is the gold-standard treatment for patients with colorectal-cancer liver metastases (CLM). This study aimed to identify prognostic factors in patients with synchronous CLM who underwent a surgical curative (R0) resection with respect to the number of metastatic nodules.

Methods

Of 1,261 CLM patients treated between January 1991 and December 2010, 339 who underwent a R0 resection for synchronous CLM were included in this retrospective analysis. Patients were grouped according to the number of CLM nodules: 1–2 CLM nodules, n = 272 (group 1) and 3–8 CLM nodules, n = 67 (group 2).

Results

The 5-year progression-free survival (PFS) rate in group 1was better than that in group 2 (P = 0.020). The multivariate analysis identified lymph-node metastasis (N2), lymphovascular invasion (LVI), and three or more CLM nodules as independent poor prognostic factors for PFS in all patients and lymph-node metastasis (N2) and LVI as independent poor prognostic factors for patients in group 1. No independent prognostic factors were identified for patients in group 2. CLM treatment method and neoadjuvant chemotherapy were not associated with survival.

Conclusion

Three or more metastatic nodules, lymph-node metastasis (N2), and LVI were independent poor prognostic factors for PFS in patients with synchronous CLM who underwent a R0 resection. The latter 2 factors were also independent prognostic factors for PFS in patients with less than 3 CLM nodules; however, in patients with three or more CLM nodules, the prognosis for PFS may be related only to liver metastasis.

Citations

Citations to this article as recorded by

Association Between Colorectal Cancer Primary Features and Liver Metastases Histological Growth Patterns: Inflammation on the Primary Tumor is Associated with Desmoplastic Growth Pattern
Ana Margarida Abrantes, Rui Caetano-Oliveira, Bárbara Oliveiros, Maria Augusta Cipriano, José Guilherme Tralhão
Clinical Colorectal Cancer.2025; 24(2): 239. CrossRef
Constructing a prognostic model for colorectal cancer with synchronous liver metastases after preoperative chemotherapy: a study based on SEER and an external validation cohort
Yixin Ding, Xiaoxi Han, Shufen Zhao, Shasha Wang, Jing Guo, Chuanyu Leng, Xiangxue Li, Kongjia Wang, Wensheng Qiu, Weiwei Qi
Clinical and Translational Oncology.2024; 26(12): 3169. CrossRef
Liver-first approach to the treatment of patients with synchronous colorectal liver metastases: a systematic review and meta-analysis
Bruno Mirandola Bulisani, Milena Arruda de Oliveira Leite, Jaques Waisberg
einstein (São Paulo).2024;[Epub] CrossRef
More Liver Metastases Detected Intraoperatively Indicates Worse Prognosis for Colorectal Liver Metastases Patients after Resection Combined with Microwave Ablation
Ling-Min Jiang, Yuan-Ping Zhang, Chen-Wei Wang, Wei-Dong Zhang, Wei He, Ji-Liang Qiu, Yi-Chuan Yuan, Bin-Kui Li, Yun-Fei Yuan, Ren-Chun Lai, Dan-Dan Hu, Yun Zheng, Alessandro Granito
Journal of Oncology.2022; 2022: 1. CrossRef
The Tumor Microenvironment in Liver Metastases from Colorectal Carcinoma in the Context of the Histologic Growth Patterns
Gemma Garcia-Vicién, Artur Mezheyeuski, María Bañuls, Núria Ruiz-Roig, David G. Molleví
International Journal of Molecular Sciences.2021; 22(4): 1544. CrossRef
lncRNA PCAT18 inhibits proliferation, migration and invasion of gastric cancer cells through miR-135b suppression to promote CLDN11 expression
Xiao-Zhan Zhang, Hong-Li Mao, Shi-Jie Zhang, Li Sun, Wen-Jing Zhang, Qing-Zhou Chen, Lei Wang, Hong-Chun Liu
Life Sciences.2020; 249: 117478. CrossRef
HIF-1α expression in liver metastasis but not primary colorectal cancer is associated with prognosis of patients with colorectal liver metastasis
Yuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saito, Chie Takasu, Shinichiro Yamada, Mitsuo Shimada
World Journal of Surgical Oncology.2020;[Epub] CrossRef
Solitary colorectal liver metastasis after curative intent surgery: prognostic factors affecting outcomes and survival
Heeji Shin, Chan Wook Kim, Jong Lyul Lee, Yong Sik Yoon, In Ja Park, Seok‐Byung Lim, Chang Sik Yu, Jin Cheon Kim
ANZ Journal of Surgery.2019; 89(1-2): 61. CrossRef
Liver Metastases and Histological Growth Patterns: Biological Behavior and Potential Clinical Implications—Another Path to Individualized Medicine?
Rui Caetano Oliveira, Henrique Alexandrino, Maria Augusta Cipriano, José Guilherme Tralhão
Journal of Oncology.2019; 2019: 1. CrossRef
Which Patients with Isolated Para-aortic Lymph Node Metastasis Will Truly Benefit from Extended Lymph Node Dissection for Colon Cancer?
Sung Uk Bae, Hyuk Hur, Byung Soh Min, Seung Hyuk Baik, Kang Young Lee, Nam Kyu Kim
Cancer Research and Treatment.2018; 50(3): 712. CrossRef
Resection after preoperative chemotherapy versus synchronous liver resection of colorectal cancer liver metastases
Chan W. Kim, Jong L. Lee, Yong S. Yoon, In J. Park, Seok-Byung Lim, Chang S. Yu, Tae W. Kim, Jin C. Kim
Medicine.2017; 96(7): e6174. CrossRef
A postoperative scoring system for post-hepatectomy early recurrence of colorectal liver metastases
Rui Mao, Jian-Jun Zhao, Xin-Yu Bi, Ye-Fan Zhang, Zhi-Yu Li, Jian-Guo Zhou, Xiao-Long Wu, Chen Xiao, Hong Zhao, Jian-Qiang Cai
Oncotarget.2017; 8(60): 102531. CrossRef
Ongoing Adjuvant/Neoadjuvant Trials in Resectable Metastatic Colorectal Cancer
Daniel Krell, Rob Glynne-Jones
Current Colorectal Cancer Reports.2016; 12(6): 303. CrossRef
Colorectal Liver Metastases: A Never Ending Story
Min Ro Lee, Jong Hun Kim
Annals of Coloproctology.2016; 32(3): 87. CrossRef

First
Prev
Page of 1
Next
Last

Search